Inclusion Criteria:

• * Aged 1 to \<18 years old, either sex, any race or ethnicity
• * Provide signed informed consent by parent or legal guardian and informed assent if applicable
• * Has a physician confirmed diagnosis of atopic dermatitis
• * Has received dupilumab for at least 12 months for the treatment of atopic dermatitis
• * Has had well-controlled atopic dermatitis on dupilumab within last 6 months (defined as POEM\<=7, EASI\<=7, or IGA\<=2)
• * Able to speak English
• * Able and willing to adhere to all study procedures

Exclusion Criteria:

• * Taking concurrent systemic medication for atopic dermatitis (e.g., methotrexate, cyclosporine, tralokinumab, abrocitinib, upadacitinib, systemic corticosteroids)
• * Using concurrent phototherapy for atopic dermatitis
• * Taking dupilumab for a clinical indication other than atopic dermatitis (such as asthma or eosinophilic esophagitis)
• * Poor control of atopic dermatitis
• * Poor control of asthma or eosinophilic esophagitis
• * Has used an investigational drug within 90 days or plan to use an investigational drug during the study period
• * Does not have health insurance or will lose health insurance during the study period